Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing dealKey Takeaways:With the drug still at an early stage of development, Pfizer has negotiated an opt-out clause in case trials do not go to planFosun Pharma's revenues from innovative drugs jumped 18.09% in the first three quarters, emerging as a growth driver for the companyIt's becoming a familiar story: the Chinese drugs industry has signed another licensin ...